JPMorgan analyst Eric Joseph upgraded Ironwood Pharmaceuticals (IRWD) to Neutral from Underweight and raised his price target for the shares to $13 from $11. While incremental color on Linzess price and growth expectations may emerge when Allergan (AGN) reports next week, the current 2019 consensus estimates are appropriately conservative, Joseph tells investors in a research note. Further, the analyst anticipates "ongoing volatility near-term" driven by interest in Ironwood's separation into two companies, which is completing in the first half of 2019.